About
Other uses include treatment of excessive male-patterned hair growth in women and Cushing's syndrome. Applied to the skin it is used for fungal skin infections such as tinea, cutaneous candidiasis, pityriasis versicolor, dandruff, and seborrheic dermatitis. In these patients the estradiol-testosterone ratio was persistently increased. The bound and free percentages of both hormones were not significantly altered. Ketoconazole, an antifungal drug, causes gynecomastia in some patients.Limited clinical studies suggest ketoconazole shampoo used either alone or in combination with other treatments may be useful in reducing hair loss in some cases. First made in 1977, ketoconazole was the first orally-active azole antifungal medication. Topical ketoconazole is also used as a treatment for dandruff (seborrheic dermatitis of the scalp) and for seborrheic dermatitis on other areas of the body, perhaps acting in these conditions by suppressing levels of the fungus Malassezia furfur on the skin.
However, in the treatment of prostate cancer, concomitant glucocorticoid administration is needed to prevent adrenal insufficiency. It was speculated that antifungal properties of ketoconazole reduce scalp microflora and consequently may reduce follicular inflammation that contributes to alopecia. Ketoconazole shampoo in conjunction with an oral 5α-reductase inhibitor such as finasteride or dutasteride has been used off label to treat androgenic alopecia. Topically administered ketoconazole is usually prescribed for fungal infections of the skin and mucous membranes, such as athlete's foot, ringworm, candidiasis (yeast infection or thrush), jock itch, and tinea versicolor.
It also inhibits androgen and glucocorticoid synthesis. Thus the link to other proteins binding androgens might be possible. 24 hours after treatment, however, the response of plasma testosterone to hCG was diminished. The diminution of testosterone synthesis could be significant as further therapeutic trials may use larger doses or more than once-daily administration.
They received the drug for seven days at a dose of 200 mg daily. A block of synthesis was demonstrated in vitro. Insurers typically require symptoms plus two low morning testosterone results and periodic labs. Work with your clinician to review opioids, glucocorticoids, ketoconazole, spironolactone, and certain antidepressants. Keep alcohol moderate (≤2 drinks/day, with alcohol‑free days each week).
As of March 2019, oral levoketoconazole (developmental code name COR-003, tentative brand name Recorlev) is phase III clinical trials for the treatment of Cushing's syndrome. In 2013, oral ketoconazole was withdrawn in the European Union and Australia, and strict restrictions were placed on the use of oral ketoconazole in the United States and Canada. This event triggered an evaluation of oral ketoconazole throughout the rest of the European Union.